Portland biotech firm ImmuCell completes $20 million expansion

Biotech firm ImmuCell Corp. of Portland has completed construction on a $20 million, pharmaceutical-grade factory that could help reduce the amount of antibiotics used in the dairy industry, Portland Press Herald reports.

The facility is designed to produce nisin, an antibacterial peptide that ImmuCell plans to sell in purified form as a natural alternative to antibiotics for treating a disease that afflicts lactating dairy cows.

If ImmuCell succeeds in obtaining U.S. Food and Drug Administration approval, the product would give it a competitive edge in the bovine health industry. Completing the production facility is a major step toward obtaining that approval.
Read full story
Immucell Press release Nov 2017

Related Posts

UNE undergraduate receives BioME grant to study rare lobster larvae

A University of New England undergraduate student has received a $5,000 grant from the Bioscience Association of Maine (BioME) to fund...

23 May 2024

New initiative unites Maine’s innovators to bolster STEM research and workforce

An $8 million grant from the National Science Foundation will fund a four-year initiative led by the University of Maine to bolster STEM...

15 May 2024

Jackson Lab hires its first-ever chief scientific officer

Jackson Laboratory, based in Bar Harbor, has hired Mary Dickinson, a globally recognized geneticist, developmental biologist, and bioengineer, as executive vice...

13 May 2024